Gerard Sanacora

List of Publications by Year
in descending order

131 papers	20,767 citations	15001 68 h-index	17373 126 g-index
135 all docs	135 docs citations	135 times ranked	16576 citing authors

#	Article	IF	Citations
1	mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression. Journal of Affective Disorders, 2022, 303, 91-97.	2.0	22
2	Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Molecular Psychiatry, 2022, 27, 2273-2281.	4.1	25
3	The stressed synapse 2.0: pathophysiological mechanisms in stress-related neuropsychiatric disorders. Nature Reviews Neuroscience, 2022, 23, 86-103.	4.9	73
4	Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. Focus (American Psychiatric Publishing), 2022, 20, 241-251.	0.4	6
5	Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting. JAMA Psychiatry, 2022, 79, 736.	6.0	11
6	Cell-type specific modulation of NMDA receptors triggers antidepressant actions. Molecular Psychiatry, 2021, 26, 5097-5111.	4.1	48
7	Intravenous arketamine for treatment-resistant depression: open-label pilot study. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 577-582.	1.8	159
8	Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial. Psychotherapy and Psychosomatics, 2021, 90, 318-327.	4.0	42
9	Absence seizures and their relationship to depression and anxiety: Evidence for bidirectionality. Epilepsia, 2021, 62, 1041-1056.	2.6	17
10	Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. American Journal of Psychiatry, 2021, 178, 352-362.	4.0	59
11	Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. American Journal of Psychiatry, 2021, 178, 383-399.	4.0	270
12	Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions. Nature Neuroscience, 2021, 24, 954-963.	7.1	207
13	Macro- and Microscale Stressâ€“Associated Alterations in Brain Structure: Translational Link With Depression. Biological Psychiatry, 2021, 90, 118-127.	0.7	24
14	Evaluating the Role of Ketamine/Esketamine in the Management of Major Depressive Disorder with Suicide Risk. CNS Drugs, 2021, 35, 1069-1079.	2.7	9
15	Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Molecular Psychiatry, 2020, 25, 1592-1603.	4.1	235
16	Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depressionâ€”TRANSFORM-3. American Journal of Geriatric Psychiatry, 2020, 28, 121-141.	0.6	325
17	Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. Journal of Affective Disorders, 2020, 260, 131-139.	2.0	21
18	Early life stress and glutamate neurotransmission in major depressive disorder. European Neuropsychopharmacology, 2020, 35, 71-80.	0.3	12

#	Article	IF	Citations
19	Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2020, 40, 287-292.	0.7	25
20	Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). Neuropsychopharmacology, 2020, 45, 1656-1663.	2.8	50
21	A randomized proof-of-mechanism trial applying the â€˜fast-failâ€™ approach to evaluating Î¹-opioid antagonism as a treatment for anhedonia. Nature Medicine, 2020, 26, 760-768.	15.2	129
22	Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. Neuropsychopharmacology, 2020, 45, 990-997.	2.8	127
23	Is This Where We Stand After Decades of Research to Develop More Personalized Treatments for Depression?. JAMA Psychiatry, 2020, 77, 560.	6.0	9
24	Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2020, 81, .	1.1	145
25	Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent. Journal of Clinical Psychiatry, 2020, 81, .	1.1	273
26	A Novel Biomarker of Neuronal Glutamate Metabolism in Nonhuman Primates Using Localized 1H-Magnetic Resonance Spectroscopy: Development and Effects of BNC375, an Î±7 Nicotinic Acetylcholine Receptor Positive Allosteric Modulator. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, , .	1.1	0
27	Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. Journal of Psychiatric Research, 2019, 110, 166-171.	1.5	41
28	Ketamine: A Paradigm Shift for Depression Research and Treatment. Neuron, 2019, 101, 774-778.	3.8	271
29	Caution Against Overinterpreting Opiate Receptor Stimulation as Mediating Antidepressant Effects of Ketamine. American Journal of Psychiatry, 2019, 176, 249-249.	4.0	21
30	Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments. Neuron, 2019, 102, 75-90.	3.8	554
31	Lower synaptic density is associated with depression severity and network alterations. Nature Communications, 2019, 10, 1529.	5.8	277
32	The Search for Rapid Acting Antidepressants: Research Synthesis and Perspectives. , 2019, , 401-413.		0
33	Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depression and Anxiety, 2019, 36, 235-243.	2.0	37
34	ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. Contemporary Clinical Trials, 2019, 77, 19-26.	0.8	34
35	A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. Drug Discovery Today, 2019, 24, 606-615.	3.2	120
36	Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. American Journal of Psychiatry, 2018, 175, 620-630.	4.0	496

#	Article	IF	Citations
37	Authorship Credit for Large Clinical Trials. JAMA - Journal of the American Medical Association, 2018, 319, 722.	3.8	2
38	Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale. Journal of Affective Disorders, 2018, 227, 11-16.	2.0	44
39	The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. American Journal of Psychiatry, 2018, 175, 150-158.	4.0	476
40	The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?. , 2018, 190, 148-158.		160
41	Ketamine: A Review for Clinicians. Focus (American Psychiatric Publishing), 2018, 16, 243-250.	0.4	7
42	The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology, 2018, 43, 2154-2160.	2.8	146
43	Hopes and Skepticism for Unraveling the Unique Mechanisms of Ketamineâ€™s Rapid Onset Antidepressant Actions in Rodent Models. Biological Psychiatry, 2018, 84, 7-8.	0.7	3
44	Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital. Journal of Clinical Psychiatry, 2018, 79, .	1.1	50
45	A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry, 2017, 74, 399.	6.0	433
46	Hippocampal Volume Changes Following Electroconvulsive Therapy: A Systematic Review and Meta-analysis. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2017, 2, 327-335.	1.1	57
47	Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2017, 2, 449-456.	1.1	47
48	Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression. Psychotherapy and Psychosomatics, 2017, 86, 162-167.	4.0	94
49	A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. Neuropsychopharmacology, 2017, 42, 2567-2574.	2.8	36
50	Characterization of GABAergic Marker Expression in the Chronic Unpredictable Stress Model of Depression. Chronic Stress, 2017, 1, 247054701772045.	1.7	81
51	Considerations on the Off-label Use of Ketamine as a Treatment for Mood Disorders. JAMA - Journal of the American Medical Association, 2017, 318, 793.	3.8	23
52	Ketamine for the Treatment of Depressionâ€”Reply. JAMA Psychiatry, 2017, 74, 971.	6.0	1
53	A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders. American Journal of Psychiatry, 2017, 174, 695-696.	4.0	88
54	Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. Neuropsychopharmacology, 2017, 42, 844-853.	2.8	99

#	Article	IF	Citations
55	Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders. Neuropsychopharmacology, 2017, 42, 193-215.	2.8	343
56	KETAMINE: A POTENTIAL RAPID-ACTING ANTISUICIDAL AGENT?. Depression and Anxiety, 2016, 33, 711-717.	2.0	31
57	KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPIDâ€ACTING ANTIDEPRESSANTS. Depression and Anxiety, 2016, 33, 689-697.	2.0	150
58	Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nature Medicine, 2016, 22, 238-249.	15.2	1,128
59	A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. American Journal of Psychiatry, 2016, 173, 816-826.	4.0	388
60	Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research. Biological Psychiatry, 2016, 80, 84-86.	0.7	2
61	What Are We Learning From Early-Phase Clinical Trials With Glutamate Targeting Medications for the Treatment of Major Depressive Disorder. JAMA Psychiatry, 2016, 73, 651.	6.0	10
62	The Use of Ketamine for the Treatment of Depression in the Context of Psychotic Symptoms. Biological Psychiatry, 2016, 79, e65-e66.	0.7	24
63	In Vivo Ketamine-Induced Changes in [11 C]ABP688 Binding to Metabotropic Glutamate Receptor Subtype 5. Biological Psychiatry, 2015, 77, 266-275.	0.7	82
64	Regulation of Extrasynaptic Glutamate Levels as a Pathophysiological Mechanism in Disorders of Motivation and Addiction. Neuropsychopharmacology, 2015, 40, 254-255.	2.8	26
65	Ketamine and Rapid-Acting Antidepressants: A Window into a New Neurobiology for Mood Disorder Therapeutics. Annual Review of Medicine, 2015, 66, 509-523.	5.0	316
66	Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?. Neuropsychopharmacology, 2015, 40, 259-267.	2.8	132
67	Riluzole Augmentation in Treatment-Refractory Obsessive-Compulsive Disorder. Journal of Clinical Psychiatry, 2015, 76, 1075-1084.	1.1	63
68	Using Our Understanding of Stress-Related Effects on Glutamate Neurotransmission to Guide the Development of Novel Treatment Strategies. , 2014, , 313-341.		0
69	Glutamate Metabolism in Major Depressive Disorder. American Journal of Psychiatry, 2014, 171, 1320-1327.	4.0	155
70	Decreased Occipital Cortical Glutamate Levels in Response to Successful Cognitive-Behavioral Therapy and Pharmacotherapy for Major Depressive Disorder. Psychotherapy and Psychosomatics, 2014, 83, 298-307.	4.0	53
71	Delayed Amnesic Syndrome after Riluzole Use in Major Depressive Disorder: A Case Report. Psychosomatics, 2013, 54, 488-492.	2.5	6
72	Scopolamine Rapidly Increases Mammalian Target of Rapamycin Complex 1 Signaling, Synaptogenesis, and Antidepressant Behavioral Responses. Biological Psychiatry, 2013, 74, 742-749.	0.7	233

#	Article	IF	Citations
73	The Revolution in Rapid-Acting Antidepressants. Biological Psychiatry, 2013, 73, 1123-1124.	0.7	0
74	From Pathophysiology to Novel Antidepressant Drugs: Glial Contributions to the Pathology and Treatment of Mood Disorders. Biological Psychiatry, 2013, 73, 1172-1179.	0.7	201
75	Rapid-Acting Glutamatergic Antidepressants: The Path to Ketamine and Beyond. Biological Psychiatry, 2013, 73, 1133-1141.	0.7	355
76	Rapid Antidepressant Effect of Ketamine in the Electroconvulsive Therapy Setting. Journal of ECT, 2012, 28, 157-161.	0.3	93
77	Cortical GABA Levels in Primary Insomnia. Sleep, 2012, 35, 807-814.	0.6	81
78	Towards a glutamate hypothesis of depression. Neuropharmacology, 2012, 62, 63-77.	2.0	831
79	Glutamate-based depression GBD. Medical Hypotheses, 2012, 78, 675-681.	0.8	41
80	Intravenous Ethanol Infusion Decreases Human Cortical Î³-Aminobutyric Acid and N-Acetylaspartate as Measured with Proton Magnetic Resonance Spectroscopy at 4 Tesla. Biological Psychiatry, 2012, 71, 239-246.	0.7	74
81	1H-[13C]-Nuclear Magnetic Resonance Spectroscopy Measures of Ketamine's Effect on Amino Acid Neurotransmitter Metabolism. Biological Psychiatry, 2012, 71, 1022-1025.	0.7	114
82	Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder. Biological Psychiatry, 2012, 72, 964-970.	0.7	121
83	Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients. Biological Psychiatry, 2012, 72, e27-e28.	0.7	187
84	The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nature Reviews Neuroscience, 2012, 13, 22-37.	4.9	1,147
85	Overview of glutamatergic neurotransmission in the nervous system. Pharmacology Biochemistry and Behavior, 2012, 100, 656-664.	1.3	224
86	Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice. Psychopharmacology, 2012, 219, 805-814.	1.5	73
87	The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS. Psychiatry Research - Neuroimaging, 2011, 191, 122-127.	0.9	170
88	Reduced Density of Calbindin Immunoreactive GABAergic Neurons in the Occipital Cortex in Major Depression: Relevance to Neuroimaging Studies. Biological Psychiatry, 2010, 67, 465-470.	0.7	144
89	Cortical Inhibition, Gamma-Aminobutyric Acid, and Major Depression: There Is Plenty of Smoke but Is There Fire?. Biological Psychiatry, 2010, 67, 397-398.	0.7	36
90	Computerized ambulatory monitoring in mood disorders: Feasibility, compliance, and reactivity. Psychiatry Research, 2010, 178, 440-442.	1.7	52

#	Article	IF	Citations
91	Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discovery Today, 2009, 14, 690-697.	3.2	60
92	Targeting glial physiology and glutamate cycling in the treatment of depression. Biochemical Pharmacology, 2009, 78, 431-439.	2.0	78
93	Do Glutamatergic Agents Represent a New Class of Antidepressant Drugs? Part 1. Journal of Clinical Psychiatry, 2009, 70, 1473-1474.	1.1	14
94	Do Glutamatergic Agents Represent a New Class of Antidepressant Drugs? Part 2. Journal of Clinical Psychiatry, 2009, 70, 1604-1605.	1.1	10
95	Reviewing Medications for Bipolar Disorder. Journal of Clinical Psychiatry, 2009, 70, e02.	1.1	2
96	Major depression: emerging therapeutics. Mount Sinai Journal of Medicine, 2008, 75, 204-225.	1.9	41
97	Chronic Riluzole Treatment Increases Glucose Metabolism in Rat Prefrontal Cortex and Hippocampus. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 1892-1897.	2.4	42
98	Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews Drug Discovery, 2008, 7, 426-437.	21.5	761
99	Serum Brain-Derived Neurotrophic Factor, Depression, and Antidepressant Medications: Meta-Analyses and Implications. Biological Psychiatry, 2008, 64, 527-532.	0.7	1,070
100	Riluzole in the Treatment of Mood and Anxiety Disorders. CNS Drugs, 2008, 22, 761-786.	2.7	150
101	New understanding of mechanisms of action of bipolar medications. Journal of Clinical Psychiatry, 2008, 69 Suppl 5, 22-7.	1.1	10
102	GABAergic Contributions to the Pathophysiology of Depression and the Mechanism of Antidepressant Action. CNS and Neurological Disorders - Drug Targets, 2007, 6, 127-140.	0.8	110
103	Antidepressant-Like Effects of Ceftriaxone in Male C57BL/6J Mice. Biological Psychiatry, 2007, 61, 250-252.	0.7	136
104	Preliminary Evidence of Riluzole Efficacy in Antidepressant-Treated Patients with Residual Depressive Symptoms. Biological Psychiatry, 2007, 61, 822-825.	0.7	189
105	Sex Differences in Diencephalon Serotonin Transporter Availability in Major Depression. Biological Psychiatry, 2006, 59, 40-47.	0.7	88
106	Cortical Î³-Aminobutyric Acid Concentrations in Depressed Patients Receiving Cognitive Behavioral Therapy. Biological Psychiatry, 2006, 59, 284-286.	0.7	102
107	N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology, 2006, 184, 254-256.	1.5	183
108	Elevated Cerebrospinal Fluid Substance P Concentrations in Posttraumatic Stress Disorder and Major Depression. American Journal of Psychiatry, 2006, 163, 637-643.	4.0	136

#	Article	IF	Citations
109	Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression. American Journal of Psychiatry, 2006, 163, 637-43.	4.0	83
110	Beyond Monoamines: Glutamatergic Function in Mood Disorders. CNS Spectrums, 2005, 10, 808-819.	0.7	254
111	Antidepressant Effect of Ketamine During ECT. American Journal of Psychiatry, 2005, 162, 1385-1386.	4.0	87
112	Sex, GABA, and nicotine: The impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy. Biological Psychiatry, 2005, 57, 44-48.	0.7	111
113	Riluzole Augmentation in Treatment-Resistant Obsessiveâ€“Compulsive Disorder: An Open-Label Trial. Biological Psychiatry, 2005, 58, 424-428.	0.7	344
114	Addition of the Î±2-Antagonist Yohimbine to Fluoxetine: Effects on Rate of Antidepressant Response. Neuropsychopharmacology, 2004, 29, 1166-1171.	2.8	79
115	Riluzole Augmentation for Treatment-Resistant Depression. American Journal of Psychiatry, 2004, 161, 2132-2132.	4.0	64
116	Subtype-Specific Alterations of Î³-Aminobutyric Acid and Glutamatein Patients With Major Depression. Archives of General Psychiatry, 2004, 61, 705.	13.8	704
117	Mutation screen of the glutamate decarboxylase-67 gene and haplotype association to unipolar depression. American Journal of Medical Genetics Part A, 2004, 124B, 81-86.	2.4	13
118	Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biological Psychiatry, 2004, 56, 497-502.	0.7	83
119	Clinical Studies Implementing Glutamate Neurotransmission in Mood Disorders. Annals of the New York Academy of Sciences, 2003, 1003, 292-308.	1.8	145
120	Cerebral benzodiazepine receptors in depressed patients measured with [123i]iomazenil SPECT. Biological Psychiatry, 2003, 54, 792-799.	0.7	57
121	Increased Cortical GABA Concentrations in Depressed Patients Receiving ECT. American Journal of Psychiatry, 2003, 160, 577-579.	4.0	414
122	Increased Occipital Cortex GABA Concentrations in Depressed Patients After Therapy With Selective Serotonin Reuptake Inhibitors. American Journal of Psychiatry, 2002, 159, 663-665.	4.0	426
123	Monoamine depletion in unmedicated depressed subjects. Biological Psychiatry, 2002, 51, 469-473.	0.7	45
124	Genotype-controlled analysis of plasma dopamine Î²-hydroxylase activity in psychotic unipolar major depression. Biological Psychiatry, 2002, 51, 358-364.	0.7	58
125	CURRENT PERSPECTIVES ON THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA, DEPRESSION, AND ANXIETY DISORDERS. Medical Clinics of North America, 2001, 85, 559-577.	1.1	30
126	ECS-Induced Mossy Fiber Sprouting and BDNF Expression Are Attenuated By Ketamine Pretreatment. Journal of ECT, 2001, 17, 27-32.	0.3	52

#	Article	IF	Citations
127	A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. Biological Psychiatry, 2000, 47, 332-337.	0.7	279
128	Impairment of GABAergic Transmission in Depression: New Insights from Neuroimaging Studies. Critical Reviews in Neurobiology, 2000, 14, 23.	3.3	132
129	Reduced Cortical Î³-Aminobutyric Acid Levels in Depressed Patients Determined by Proton Magnetic Resonance Spectroscopy. Archives of General Psychiatry, 1999, 56, 1043.	13.8	547
130	Reduced brain serotonin transporter availability in major depression as measured by [123I]-2Î²-carbomethoxy-3Î²-(4-iodophenyl)tropane and single photon emission computed tomography. Biological Psychiatry, 1998, 44, 1090-1098.	0.7	456
131	Evidence for GABAergic and Glutamatergic Involvement in the Pathophysiology and Treatment of Depressive Disorders. , 0, , 739-749.		0